Cooper Companies Raised to Buy at Jefferies on Valuation Disconnect
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17.
Jefferies Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $105
Jefferies analyst Michael Sarcone maintains $Alcon(ALC.US)$ with a buy rating, and adjusts the target price from $100 to $105.According to TipRanks data, the analyst has a success rate of 36.8% and
Jefferies Gives a Buy Rating to Alcon (ALC)
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
Morgan Stanley Cuts STAAR to Underweight, Cites Growth Expectations
Medical Technology Companies Poised for Another 'Solid' Quarter, Morgan Stanley Says
Most medical technology companies appear well positioned as they prepare to report their Q2 financial results, analysts at Morgan Stanley said Monday, citing recent discussions with the companies
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
Express News | Alcon Inc : Morgan Stanley Raises to Equal-Weight
Express News | Alcon Inc : Morgan Stanley Raises Target Price to $85.00 From $65.00
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
The Medical Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas.
BTIG Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $96
BTIG analyst Ryan Zimmerman maintains $Alcon(ALC.US)$ with a buy rating, and adjusts the target price from $92 to $96.According to TipRanks data, the analyst has a success rate of 46.6% and a total
Express News | Alcon AG : Btig Raises Target Price to $96 From $92
Morgan Stanley Upgrades Alcon to Equalweight From Underweight, Raises Price Target to $85 From $65
Alcon (ALC) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $70 to $105.Price: 91.23, Change: -0.51, Percent Change: -0.56
Express News | Needham Reiterates Buy on Alcon, Maintains $101 Price Target
Alcon Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 11.55% Needham $101 → $101 Reiterates Buy → Buy 05/15/2024 3.82% Wells Fargo $89 → $94
STAAR Surgical Gains Amid Takeover Speculation
Wells Fargo Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $94
Wells Fargo analyst Larry Biegelsen maintains $Alcon(ALC.US)$ with a buy rating, and maintains the target price at $94.According to TipRanks data, the analyst has a success rate of 58.1% and a total
UBS Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $102.68
UBS analyst Graham Doyle maintains $Alcon(ALC.US)$ with a buy rating, and adjusts the target price from $102.57 to $102.68.According to TipRanks data, the analyst has a success rate of 48.9% and a
UBS Sticks to Its Buy Rating for Alcon (ALC)